BE1002249A4 - Compositions pharmaceutiques. - Google Patents

Compositions pharmaceutiques. Download PDF

Info

Publication number
BE1002249A4
BE1002249A4 BE8701354A BE8701354A BE1002249A4 BE 1002249 A4 BE1002249 A4 BE 1002249A4 BE 8701354 A BE8701354 A BE 8701354A BE 8701354 A BE8701354 A BE 8701354A BE 1002249 A4 BE1002249 A4 BE 1002249A4
Authority
BE
Belgium
Prior art keywords
pharmaceutical compositions
methyl
acceptable salts
physiologically acceptable
ranitidine
Prior art date
Application number
BE8701354A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40347948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE1002249(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of BE1002249A4 publication Critical patent/BE1002249A4/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour l'utilisation dans le traitement des désordres gastro-intestinaux, caractérisée en ce qu'elle contient de la 1,2,3,9-tétrahydro-9-méthyl-3-[(2-méthyl-1H-imidazol-1-yl)méthyl]-4H-carbazol-4-one, l'un de ses sels physiologiquement acceptable ou solvate, et de la ranitidine ou l'un de ses sels physiologiquement acceptable.
BE8701354A 1985-06-25 1987-11-27 Compositions pharmaceutiques. BE1002249A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858516083A GB8516083D0 (en) 1985-06-25 1985-06-25 Heterocyclic compounds
GB868628474A GB8628474D0 (en) 1985-06-25 1986-11-28 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BE1002249A4 true BE1002249A4 (fr) 1990-11-06

Family

ID=40347948

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8701354A BE1002249A4 (fr) 1985-06-25 1987-11-27 Compositions pharmaceutiques.

Country Status (22)

Country Link
US (2) US4753789A (fr)
EP (2) EP0226266B1 (fr)
JP (2) JPS6253920A (fr)
AT (2) ATE134510T1 (fr)
AU (2) AU609028B2 (fr)
BE (1) BE1002249A4 (fr)
CA (1) CA1296637C (fr)
CH (1) CH672068A5 (fr)
CY (1) CY2000A (fr)
DE (2) DE3650488T2 (fr)
DK (1) DK624687A (fr)
FR (1) FR2613934B1 (fr)
GB (3) GB8516083D0 (fr)
HK (1) HK82597A (fr)
IE (1) IE60908B1 (fr)
IL (1) IL84638A (fr)
IT (1) IT1211937B (fr)
NL (1) NL8702853A (fr)
NZ (1) NZ222743A (fr)
SE (1) SE8704747L (fr)
SG (1) SG43311A1 (fr)
ZA (1) ZA878927B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0201165B1 (fr) * 1985-03-14 1994-07-20 Beecham Group Plc Médicaments pour le traitement de l'éméticité
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
IL84845A0 (en) * 1986-12-17 1988-06-30 Glaxo Group Ltd Pharmaceutical compositions comprising a certain carbazolone derivative or a salt thereof
GB8630079D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB8630080D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
JPH0754759B2 (ja) * 1987-04-27 1995-06-07 日本電信電話株式会社 プラズマ処理方法および装置並びにプラズマ処理装置用モード変換器
US4943428A (en) * 1987-07-10 1990-07-24 Wright State University Stimulation of serotonin-1A receptors in mammals to alleviate motion sickness and emesis induced by chemical agents
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
GB8816187D0 (en) * 1988-07-07 1988-08-10 Glaxo Group Ltd Medicaments
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
AU627221B2 (en) * 1988-09-27 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Pyridoindole derivatives and processes for preparation thereof
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5039528A (en) * 1989-12-11 1991-08-13 Olney John W EAA antagonists as anti-emetic drugs
US4971651A (en) * 1990-02-05 1990-11-20 Hitachi, Ltd. Microwave plasma processing method and apparatus
AU2254692A (en) * 1991-06-26 1993-01-25 Sepracor, Inc. Methods and compositions for treating emesis, nausea and other disorders using optically pure s(-) ondansetron
JPH06508836A (ja) * 1991-06-26 1994-10-06 セプラコア，インコーポレーテッド 光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
PT533280E (pt) * 1991-09-20 2001-01-31 Glaxo Group Ltd Novas utilizacoes medicas para antagonistas de taquiquinina
JPH08507514A (ja) * 1993-03-08 1996-08-13 藤沢薬品工業株式会社 脳血管性疾患を治療または予防するための薬物
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
CA2371822A1 (fr) 1999-03-01 2000-09-08 Sepracor Inc. Procedes de traitement de l'apnee et de troubles de l'apnee a l'aide de r(+) ondansetron optiquement pur
KR100434390B1 (ko) * 2001-04-20 2004-06-04 안국약품 주식회사 1,2,3,9-테트라히드로-9-메틸-3-[(2-메틸-1ｈ-이미다졸-1-일)메틸]-4ｈ-카바졸-4-온을 유효성분으로 하는 비강분무용조성물
AU2003302072A1 (en) * 2002-11-15 2004-06-15 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
DE602004005814T2 (de) * 2003-01-13 2008-01-10 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
CA2565854A1 (fr) * 2004-05-07 2005-11-17 Taro Pharmaceutical Industries Ltd. Procede de preparation de chlorhydrate dihydrate d'ondansetron ayant une granulometrie definie
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
EP1940366B9 (fr) * 2006-10-24 2009-12-02 Helsinn Healthcare S.A. Capsules molles comprenant du chlorhydrate de palonosétron ayant une stabilité et une biodisponibilité améliorées
JP2010050046A (ja) 2008-08-25 2010-03-04 Hitachi High-Technologies Corp プラズマ処理装置
CN102892405A (zh) 2009-12-28 2013-01-23 莫诺索尔克斯有限公司 包含昂丹司琼的可经口施用的膜剂型
MX342993B (es) 2013-04-25 2016-10-13 Inst Mexicano Del Petróleo Proceso de obtencion de copolimeros aleatorios derivados del acido itaconico y/o sus isomeros y alquenil sulfonatos de sodio y uso del producto obtenido.
EP3589369A4 (fr) 2017-01-09 2020-03-18 DAS-MG, Inc. Utilisation et composition pour traiter la myasthénie grave et d'autres syndromes myasthéniques

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040489A1 (fr) * 1980-05-17 1981-11-25 FISONS plc Mélanges, sels, emballages et compositions pharmaceutiques contenant l'acide 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyrane-2-carboxylique ou un de ses dérivés et une antihistamine antagoniste des récepteurs H2
EP0226266A2 (fr) * 1985-06-25 1987-06-24 Glaxo Group Limited Utilisation d'un dérivé du tétrahydrocarbazolone pour la fabrication de médicaments
EP0275669A1 (fr) * 1986-12-17 1988-07-27 Glaxo Group Limited Application des dérivés hétérocycliques pour la fabrication de médicaments

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE894285A (fr) * 1981-09-04 1983-03-02 Glaxo Group Ltd Composition pharmaceutique contenant un medicament anti-inflammatoire et de la ranitidine ou un sel de ce compose
DE3445377A1 (de) * 1983-12-23 1985-07-04 Sandoz-Patent-GmbH, 7850 Lörrach Carbocylische und heterocyclische carbonsaeureester und -amide von ueberbrueckten und nicht ueberbrueckten cyclischen stickstoffhaltigen aminen oder alkoholen
IE57809B1 (en) * 1984-01-25 1993-04-21 Glaxo Group Ltd 1,2,3,9-tetrahydro-3-(imidazol-1-ylmethyl)-4h-carbazol-4 one derivatives
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
AU583343B2 (en) * 1985-01-23 1989-04-27 Glaxo Group Limited Heterocyclic compounds
EP0201165B1 (fr) * 1985-03-14 1994-07-20 Beecham Group Plc Médicaments pour le traitement de l'éméticité

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040489A1 (fr) * 1980-05-17 1981-11-25 FISONS plc Mélanges, sels, emballages et compositions pharmaceutiques contenant l'acide 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyrane-2-carboxylique ou un de ses dérivés et une antihistamine antagoniste des récepteurs H2
EP0226266A2 (fr) * 1985-06-25 1987-06-24 Glaxo Group Limited Utilisation d'un dérivé du tétrahydrocarbazolone pour la fabrication de médicaments
EP0275669A1 (fr) * 1986-12-17 1988-07-27 Glaxo Group Limited Application des dérivés hétérocycliques pour la fabrication de médicaments

Also Published As

Publication number Publication date
JPS63198623A (ja) 1988-08-17
EP0226266A3 (en) 1990-01-24
GB2200046A (en) 1988-07-27
IL84638A (en) 1992-05-25
EP0226266A2 (fr) 1987-06-24
AU609028B2 (en) 1991-04-26
NL8702853A (nl) 1988-06-16
ATE134510T1 (de) 1996-03-15
AU8191487A (en) 1988-06-02
AU6703786A (en) 1988-06-30
GB8628474D0 (en) 1987-01-07
CA1296637C (fr) 1992-03-03
AT395374B (de) 1992-12-10
DE3740351A1 (de) 1988-06-09
GB8727836D0 (en) 1987-12-31
HK82597A (en) 1997-06-27
GB8516083D0 (en) 1985-07-31
IE60908B1 (en) 1994-08-24
EP0226266B1 (fr) 1996-02-28
DE3650488T2 (de) 1996-09-05
ZA878927B (en) 1988-10-26
EP0431443A3 (en) 1991-09-18
SE8704747L (sv) 1988-05-29
US4753789A (en) 1988-06-28
JPS6253920A (ja) 1987-03-09
US4929632A (en) 1990-05-29
ATA312587A (de) 1992-05-15
EP0431443A2 (fr) 1991-06-12
CY2000A (en) 1997-12-05
FR2613934B1 (fr) 1993-07-09
DK624687D0 (da) 1987-11-27
GB2200046B (en) 1990-09-26
CH672068A5 (fr) 1989-10-31
IT1211937B (it) 1989-11-08
DK624687A (da) 1988-05-29
IT8748643A0 (it) 1987-11-27
FR2613934A1 (fr) 1988-10-21
JPH0324447B2 (fr) 1991-04-03
NZ222743A (en) 1991-09-25
AU616386B2 (en) 1991-10-31
SE8704747D0 (sv) 1987-11-27
DE3650488D1 (de) 1996-04-04
IE873230L (en) 1988-05-28
SG43311A1 (en) 1997-10-17

Similar Documents

Publication Publication Date Title
BE1002249A4 (fr) Compositions pharmaceutiques.
TNSN98182A1 (fr) Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
CA2206837A1 (fr) Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN94078A1 (fr) Nouvelle formule pharmaceutique
FR2378523A1 (fr) Medicament pour le traitement de l'acne
TNSN98155A1 (fr) Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation
TNSN99252A1 (fr) Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant.
TNSN97139A1 (fr) Derives d'acides d'arylsulfonylaminohydroxamiques
TNSN99110A1 (fr) Inhibiteurs non peptidiques de l'adhesion cellulaire sous la dependance de vla-4, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2445146A1 (fr) Medicament a prise orale contenant une substance inhibitrice de l'inflammation et un ou plusieurs phospholipides
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
TNSN99001A1 (fr) Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques
TNSN99198A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
TNSN99214A1 (fr) Azalides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
IL84844A0 (en) Pharmaceutical compositions comprising a certain carbazolone derivative or a salt thereof
BE1002295A5 (fr) Medicaments.
FR2377804A1 (fr) Compositions analgesiques et anti-inflammatoires comprenant des derives de chromone
BE1002255A5 (fr) Medicaments.
TNSN00142A1 (fr) Complexe d'eletriptan et d'une sulfobutylether- betacyclodextrine, procede pour sa preparation et compositions pharmaceutiques les contenant.
DZ2564A1 (fr) Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.

Legal Events

Date Code Title Description
RE Patent lapsed

Effective date: 20041130

RE Patent lapsed

Effective date: 20041130